GNE-272 is a selective inhibitor of CBP/EP300 (IC50: 0.02, 0.03, and 13 μM for CBP, EP300, and BRD4, respectively) and a selective in vivo probe for CBP/EP300.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 6-8 weeks | $ 158 | |
4 mg | 6-8 weeks | $ 284 | |
8 mg | 6-8 weeks | $ 480 | |
20 mg | 6-8 weeks | $ 873 | |
40 mg | 6-8 weeks | $ 1318 |
Description | GNE-272 is a selective inhibitor of CBP/EP300 (IC50: 0.02, 0.03, and 13 μM for CBP, EP300, and BRD4, respectively) and a selective in vivo probe for CBP/EP300. |
Targets&IC50 | BRD4:13 μM, CBP:0.02 μM, EP300:0.03 μM |
In vitro | GNE-272 does not inhibit any target at >30% when tested at 10 μM in 35 kinase panel and 42 receptors off-target screening panel. GNE-272 does not inhibit (>10 μM, top concentration) several cytochrome P450s (3A4, 1A2, 2C9, 2C19, 2D6). GNE-272 is exquisitely selective for CBP/ EP300 and remarkably selective (650-fold) over BRD4. The compound has good potency in the BRET cellular assay. GNE-272 is shown to inhibit the expression of MYC10 (MV4?11 cell line) (EC50: 0.91 μM) and a good correlation between the BRET and MYC cellular assays is observed. |
In vivo | GNE-272 displays a marked antiproliferative effect in hematologic cancer cell lines. Which modulates MYC expression in vivo that corresponds with antitumor activity in an AML tumor model. GNE-272 shows low clearance following a 1 mg/ kg intravenous dose in a mouse PK experiment and good oral bioavailability when dosed at 100 mg/kg, reaching an unbound Cmax of 26 μM. |
CAS No. | 1936428-93-1 |
Chemical Formula | C22H25FN6O2 |
Molecular Weight | 424.48 |
Solubility | DMSO: 100 mg/mL (235.59 mM), Need ultrasonic |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom